secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0001104659-25-024432
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco signs research agreement with WEDterinary for $4M gene therapy in cats; four directors departing
--------------------------------------------------------------------------------

- Board to shrink to 11 directors; Bilbrey, Turner, Wallace won't stand for re-election; Doyle resigned.
- Research agreement with WEDterinary (33%-owned by Doyle) for targeted gene therapy treating chronic kidney disease in cats.
- Elanco US will pay up to $4 million to fund WED research, securing negotiation rights to resulting IP.
- Doyle will continue advising Elanco on animal health innovation; Paul Herendeen to chair Finance Committee.
- Agreement funded within R&D operating expenses; approved by Audit Committee under related person policy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000110465925024432/0001104659-25-024432-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000110465925024432/tm259453d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-024432

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer